Article Details
Retrieved on: 2017-12-28 06:41:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div><b>Benchmark Capital</b> Advisors raised its position in Bioline RX Ltd (NASDAQ:BLRX) by 227.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 144,000 shares of the biotechnology company's stock after ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here